KaloBios Confirms Communications with Majority Shareholder Group

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2015  -- KaloBios Pharmaceuticals, Inc. (KBIO) today announced that it has been informed that an investor group comprised of Martin Shkreli and associates together have acquired more than 50% of the outstanding shares of KaloBios, and that the company is in discussions with Mr. Shkreli regarding possible direction for the company to continue in operation. Mr. Shkreli is the founder and chief executive officer of Turing Pharmaceuticals, a privately held biopharmaceutical company.

"We have received communications from Mr. Shkreli informing us of his group's ownership position, and a proposal to continue the company's operations," said Ronald Martell, Executive Chairman of KaloBios. "Our board of directors is prepared to entertain any constructive proposal, which we will act upon promptly. Addressing short-term cash needs is our first priority, and we continue to be open to further dialogue," he concluded.

Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy

Preliminary Pharmacokinetic Data Demonstrate Promising Extended-Release Profiles

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2015  -- Ocera Therapeutics, Inc. (OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced positive results from the Company’s Phase 1 study of the oral formulation of OCR-002, ornithine phenylacetate, in healthy subjects.  OCR-002 exhibited encouraging extended-release properties, demonstrated a desirable pharmacokinetic (PK) profile and was well-tolerated.

Ceapro Inc. Reports Third Quarter 2015 Financial Results and Provides Corporate Update

- Company reports record sales with the highest quarterly revenue performance in its history - Company poised to fully leverage its proprietary enabling technologies to enter well established and growing markets

EDMONTON, ALBERTA--(Nov 12, 2015) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and nine-month periods ended September 30, 2015 and provided a corporate update.

Financial Highlights for the Third Quarter of 2015

• Total sales of $3,079,000 in 3Q 2015 vs. $2,445,000 in 3Q 2014, an increase of 26% and the highest quarterly revenue performance in the Company's history.

  Published: 12 November 2015

  Written by Editor

  Financial Results   Up on News   TSXV  

  Read more: Ceapro Inc ( CZO )